Steady advances are occurring in immunotherapy resulting in two of this week's most interesting articles describing bispecific T-cell engager antibodies (BiTE Ab). Click the link to read more.
Steady advances are occurring in immunotherapy resulting in two of this week's most interesting articles describing bispecific T-cell engager antibodies (BiTE Ab). Click the link to read more.